Introduction components [7] . XPO1 inhibition also leads to nuclear retention of host factors essential to viral replication, and 48
inflammatory molecules like cytokine transcripts and transcription factors responsible for immunopathology.
49
Verdinexor attenuates inflammation by forcing nuclear retention of proinflammatory cytokine transcriptional 50 inhibitors (such as IκB, RXRα, and PPARγ) (Fig. 2) . XPO1-mediated translocation of the tumor suppressor 51 protein GLTSCR2 to the cytoplasm results in attenuation of RIG-I and decreased interferon-β production [8] .
52
Therefore, verdinexor has potential for treating viruses by inhibiting viral replication and relieving symptoms 53 through suppression of inflammatory responses. To assess potential off-target toxicities associated with verdinexor, a panel of in vitro protein binding 61 assays were performed to evaluate the potential interaction of verdinexor with 104 principal receptor/ligand 62 interactions (peptides, growth factors, ion channels, transporters, kinases, cysteine proteases (including 63 caspases and matrix metalloproteinases) (Study No. KS-1016 and PE-50946871) . At a concentration of 10 μM, 64 none of the enzymes, receptors, transporters, kinases, or cysteine proteases were significantly affected by reported previously in HFF cells [13] . Optical densities were determined at 550nm [9] .
143
Yield reduction assays for HCMV were performed on monolayers of HFF cells prepared in 96-well plates 144 and incubated at 37°C for 1d to allow the cells to reach confluency. Media was then aspirated from the wells 145 were infected at a high multiplicity of infection (MOI). At 1h following infection, the inocula were removed and the 146 monolayers rinsed with fresh media. Compounds were then diluted in assay media consisting of MEM with Earl's 147 salts supplemented with 2% FBS, L-glutamine, penicillin, and gentamycin. Solutions ranging from 0.0032-10µM 148 in primary assay and 0.032-100µM in secondary assay were added to the wells and the plates were incubated 149 for various times, depending on the virus used and represents the length of a single replication cycle for the S1 virus. A duplicate set of dilutions were also performed but remained uninfected to serve as a cytotoxicity control that reduced virus titer by 50% (EC 50 ) was interpolated from the experimental data.
155

MCMV/GPCMV
156 Cytotoxicity assay was performed in a manner analogous to HCMV (see above). (secondary) were added to triplicate wells and the plates were incubated for various times, depending on the 164 virus used. For MCMV and GPCMV, the cell monolayer was stained with 1% neutral red solution for 4h at which 165 time the stain was aspirated and cells were washed with PBS. For all assays, plaques were enumerated using 166 a stereomicroscope and the concentration of compound that reduced plaque formation by 50% (EC 50 ) was 167 interpolated from the experimental data.
168
EBV 169
Cytotoxicity assay was performed in a manner analogous to KSHV (see above).
170
For Primary assay, Akata cells latently infected with EBV were induced to undergo lytic infection by 171 addition of 50μg/ml of a goat anti-human IgG [14] and a dose-range of verdinexor (0.032 to 100 μM) was added 172 for 72hr. Denaturation buffer was added and an aliquot aspirated through an Immobilon nylon membrane with EBV DNA were hybridized overnight followed by washes in 0.2× SSC and 0.1× SSC both with 0.1% SDS. [15] .
196
To quantify virus, compound was diluted from 0.008-100µM and added to BCBL-1 cells induced to 197 undergo a lytic infection by the addition of 100ng/ml phorbol 12-myristate 13-acetate (PMA) (Promega). After 7d,
198
total DNA was prepared, and viral DNA was quantified by qPCR (S1 Table for primer/probe sequences). Plasmid provide absolute quantification of viral DNA and EC 50 [10] .
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For AdV cytotoxicity assay, at 6d post-infection plates were stained with tetrazolium-based MTS incubation, wells were visually scored for infection and TCID 50 , EC 50 , CC 50 and SI were calculated for each 208 sample.
209
BKPyV 210
Cytotoxicity assay was performed in a manner analogous to KSHV above. in 96-well plates according to established laboratory protocols with the compounds added 1h post-infection to 217 identify compounds that inhibit early stages of replication including adsorption and entry. Genome copy number 218 was determined by methods described above.
219
JCPyV 220
Cytotoxicity assay was performed in a manner analogous to KSHV above. Evaluation of compounds 221 against JCPyV virus was done in COS7 cells [18] with the plasmid pMP508 to provide a standard curve for 222 quantification.
223
Primary evaluation of compounds against JC polyoma virus were also performed by methods similar to 224 those for BK virus primary assays but were done in COS7 cells and utilized the MAD-4 strain of JCV. Viral DNA 225 was quantified (S1 Table) together with the plasmid pMP508 to provide a standard curve for absolute 226 quantification. Secondary assays against JCV were also performed in COS7 cells by methods similar to those 227 for BK virus to identify if verdinexor inhibited adsorption or entry of the virus. 
EBV replication is antagonized by treatment with verdinexor 249
In this study, we determined the efficacy of verdinexor to inhibit replication in vitro against EBV infection 250 of Akata cells, with EC 50 values in the range of >0.48µM (primary screen) to 0.05µM (secondary screen) ( Fig. 3) .
251
This correlated to an SI of <1 in primary screen measured by DNA hybridization and 7 in a secondary assay that 252 used qPCR. Interestingly, a similar pattern was observed in control-treated cells, with acyclovir administration 253 resulting in EC 50 values of 15.03µM in primary assay and 7.90µM in a secondary screen (S1 Fig.) . This correlated Short Title: Verdinexor treatment of opportunistic viral infections 12 254
to SI values of >7 and >13, respectively. These results indicate that inhibition of nuclear export with verdinexor values of 0.19µM and 2.5µM, respectively (Fig. 3) . Taking cytotoxicity into consideration, we observed an SI of 259 9 in the primary screen, and 29 in the secondary screen. Treatment of HCMV-infected HFF cells with the 260 nucleoside analogue ganciclovir resulted in EC 50 values of 0.51µM in primary screen and 4µM in secondary with 261 SI values of >196 and >25 respectively (S1 Fig.) . With these data in hand, we were next interested if replication 262 of cytomegaloviruses tropic for small animals would be efficiently inhibited by verdinexor treatment. verdinexor produced an EC 50 value of <0.8µM and a SI of >3.45 (Fig. 3) . This compares to cidofovir, which was while cidofovir produced an EC 50 of 1.68µM with a concomitant SI of >36 (S1 Fig.) . Despite differing CC 50 values 283 between the screens, these results provide rationale for further examination of the efficacy of verdinexor against 284 KSHV in models of KSHV infection. Verdinexor also has anti-oncogenic properties, opening the possibility of an 285 alternative mechanism of inhibiting KSHV-induced malignancies.
263
Verdinexor is efficacious in lowering replication of MCMV in MEF cells
286
Adenovirus infection is inhibited by treatment with verdinexor 287
Initial testing of verdinexor against Ad5 infection in HeLa cells demonstrated efficacy with an EC 50 value 288 of >0.18µM (Fig. 3) . However, these cells proved to be highly sensitive to the cytotoxic effects of antiviral 289 treatment and as such we did not observe efficacious SI values. In a secondary screening, the EC 50 value for 290 verdinexor was <0.03µM and an SI of >3 (Fig. 3) . A highly potent neutralizing anti-Ad5 monoclonal antibody was 291 used as a positive control, and treatment resulted in SI of >50 and >41 in primary and secondary assays, 292 respectively (S1 Fig.) . With this in vitro data, we feel that further studies of verdinexor efficacy against AdV 293 infection should be considered using different non-cancerous cell lines to address observed cytotoxicity.
294
Efficacy of verdinexor against the polyomaviruses BKPyV and JCPyV 295
Treatment with verdinexor against BKPyV infection in HFF cells resulted in an SI of >1 in primary assays,
296
and 4 in secondary screen with EC 50 values of 7.62 and 2.29µM respectively when measured by qPCR ( Fig. 4) . resulted in an EC 50 of 3.86µM and an SI of 17. Thus, despite similar efficacious concentrations of drug, cytotoxic 300 levels varied between drugs in these cells resulting in differences in SI. The results of additional suggest 301 additional testing of BKPyV and JCPyV in alternate cell lines will serve to assess the true ability of verdinexor to 302 inhibit polyomavirus replication. Efficacy of verdinexor against 2 strains of HPV in 2 different cell lines these cells. Interestingly we observed similar lack of efficacy in the control treatment cells, with the MEK inhibitor 309 Uo 126 producing an SI of >1 (S2 Fig.) . This appears to be either a virus strain or cell type-specific result, and may 310 not be indicative of verdinexor and/or Uo 126 performance in vivo, especially in light of the results of the primary 311 screen with HPV-11. Taken together, these data suggest verdinexor may have the potential to serve as a type-312 specific and potent antiviral compound for the treatment of certain HPV-related diseases.
314
Discussion
315
Opportunistic infections associated with immunodeficiency are a burgeoning field of translational 316 research. Limited therapies exist to treat these normally benign infections, and with increasing numbers of 317 patients displaying symptoms of immunodeficiency, the need for novel strategies by which to treat opportunistic 318 viral infections is high.
319
Verdinexor is a member of a class of small molecules which bind the nuclear export protein XPO1 to 320 inhibit its function. The result is nuclear accumulation of proteins (nearly 220 identified) that utilize XPO1 for 321 translocation into the cytoplasm. Verdinexor has shown promising potential as a broad-spectrum antiviral drug [6, 7, 20] . It demonstrates a dual mechanism of action, by inhibiting replication of viruses that utilize XPO1 323 machinery for replication, and relieving virus-induced inflammation [6] . Importantly, inhibition of XPO1 does not 324 rely on immune status for its antiviral effects, and viral resistance is minimized by targeting a host cell protein.
322
In 325 a study with influenza A, 10 passages of the virus in the presence of verdinexor resulted in highly attenuated targets the underlying causes of immunopathology (namely inflammation) in immunocompromised individuals while simultaneously inhibiting viral replication that can occur when opportunistic viruses develop active infection 7 when measured by qPCR. Acyclovir was observed to have higher EC 50 and lower SI values when measured 332 by DNA hybridization, a pattern also observed for verdinexor treatment. This may be an indication that qPCR 333 was more sensitive for measuring subtle differences in viral titer. We hypothesize that the efficacy of verdinexor 334 could be explained by the dependence of the EBV protein SM on XPO1-mediated nuclear export (Fig. 5) [22] .
335
SM is an adaptor protein involved in the nucleocytoplasmic export of mRNAs encoding lytic EBV genes. Blockade
336
of this export should prevent shuttling of these mRNAs to the cytoplasm for translation. Thus, this proposed 337 mechanism of action, inhibition of viral translation, may be more accurately measured by qPCR. 
343
We observed a SI value for verdinexor treatment of HCMV-infected cells exceeding that of ganciclovir 344 positive control. One possible explanation from the literature is the requirement of HCMV tegument protein pp65 345 (UL83) to localize to the cytoplasm where it participates in virion assembly (Fig. 5 ). Prior to its cytoplasmic 346 localization, pp65 is found in the nucleus where it utilizes XPO1 for its export [23] . Blockade of XPO1 by 347 verdinexor presumably causes accumulation of pp65 in the nucleus, where it is unable to participate in virion 348 assembly. Nuclear sequestration of another tegument protein, UL94, a protein carrying an XPO1-dependent 349 NES sequence would be predicted to hinder viral replication as well. We also observed very promising SI values 350 for verdinexor treatment of murine CMV and guinea pig CMV-infected cells, warranting further investigation of 351 verdinexor treatment in in vivo mouse and guinea pig models.
352
In KSHV, blockade of XPO1-dependent nuclear export with verdinexor was shown to reduce viral 353 replication, likely via inhibition of multifunctional viral protein ORF45 (Fig. 5 ). ORF45 is normally localized to the 
362
Adenoviruses are some of the most ubiquitous viruses in the human population. We observed verdinexor 363 inhibition of viral replication at concentrations <30nM. Adenoviral protein transcription is thought to be dependent 364 on XPO1-mediated nuclear export of the viral major late transcription unit (MLTU; Fig. 5 induce apoptosis in oligodendrocytes [37] . Thus, on the basis of current knowledge, we believe there are multiple multiple viral infections. 
587
Results of positive control treatment against viral infections. EC 50 values are plotted in blue, CC 50 values are 588 plotted in green, and the SI value for each assay is plotted in orange.
